Use of rapamycin-impregnated stents in coronary arteries

Sousa, J. Eduardo; Sousa, Amanda G.M.R.; Costa, Marco A.; Abizaid, Alexander; Feres, Fausto

doi:10.1016/s0041-1345(03)00215-x

Cited by 22 publications

(9 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Rapamycin, disrupting these protein complexes, may impair either upstream signaling, leading to mTOR activation, or kinase access to downstream substrates [25,26]. Recently, rapamycin received approval as a component of cardiac arterial stents because of its potent antiproliferative effects on fibroblasts responsible for restenosis following such procedures [27].…”

Section: Rapamycin (Sirolimus)mentioning

confidence: 99%

The Potential Role of mTOR Inhibitors in Non-Small Cell Lung Cancer

2008

View full text Add to dashboard Cite

After completing the course, the reader will be able to:1. Describe the PI3K growth pathway.2. Describe the molecular mechanism of action of mTOR inhibitors. Describe the preliminary clinical results of mTOR inhibitors in NSCLC.Access and take the CME test online and receive 1 AMA PRA Category 1 Credit ™ at CME.TheOncologist.com CME CME ABSTRACTThe mammalian target of rapamycin (mTOR), a serine/threonine kinase, is a downstream mediator in the phosphatidylinositol 3-kinase/Akt signaling pathway, which plays a critical role in regulating basic cellular functions including cellular growth and proliferation. Currently, the mTOR inhibitor rapamycin and its analogues (CCI-779, RAD001, AP23573), which induce cell-cycle arrest in the G 1 phase, are being evaluated in cancer clinical trials. The mTOR inhibitors appear to be well tolerated, with skin reactions, stomatitis, myelosuppression, and metabolic abnormalities the most common toxicities seen. These adverse events are transient and reversible with interruption of dosing. Several pieces of evidence suggest a certain antitumor activity, including tumor regressions and prolonged stable disease, which has been reported among patients with a variety of malignancies, including non-small cell lung cancer (NSCLC). These promising preliminary clinical data have stimulated further research in this setting. Here, we review the basic structure of the pathway together with current results and future developments of mTOR inhibitors in the treatment of NSCLC patients. The Oncologist

show abstract

Section: Rapamycin (Sirolimus)mentioning

confidence: 99%

The Potential Role of mTOR Inhibitors in Non-Small Cell Lung Cancer

2008

View full text Add to dashboard Cite

show abstract

“…It has been shown to have potent immunosuppressive activity and to inhibit Tcell activation and proliferation [6][7][8][9][10][11]. As a consequence of its potent pharmacological properties, it is successfully used to impregnate stents inserted in coronary arteries during surgical applications, preventing fatal infection and rejection adverse effect [12,13].…”

Section: Introductionmentioning

confidence: 99%

Evaluation of rapamycin chemical stability in volatile-organic solvents by HPLC

Ricciutelli

Martino

Barboni

et al. 2006

Journal of Pharmaceutical and Biomedical Analysis

View full text Add to dashboard Cite

“…For example, paclitaxel and sirolimus both have anti-proliferative properties (inhibit proliferation of vascular smooth muscle and endothelial cells) and also have potent anti-inflammatory function and affect cell migration and motility 16,17. Compartmentalizing these agents as either antiproliferative or anti-inflammatory will understate the breadth of their biological activity.…”

Section: Pharmacology Of Desmentioning

confidence: 99%

Drug-eluting coronary stents – focus on improved patient outcomes

Jaffery

Prasad²,

Lee³

et al. 2011

PROM

View full text Add to dashboard Cite

The development of stent has been a major advance in the treatment of obstructive coronary artery disease since the introduction of balloon angioplasty. Subsequently, neointimal hyperplasia within the stent leading to in-stent restenosis emerged as a major obstacle in long-term success of percutaneous coronary intervention. Recent introduction of drug-eluting stents is a major breakthrough to tackle this problem. This review article summarizes stent technology, reviews progress of drug-eluting stents and discusses quality of life, patient satisfaction, and acceptability of percutaneous coronary intervention.

show abstract

Use of rapamycin-impregnated stents in coronary arteries

Cited by 22 publications

References 17 publications

The Potential Role of mTOR Inhibitors in Non-Small Cell Lung Cancer

The Potential Role of mTOR Inhibitors in Non-Small Cell Lung Cancer

Evaluation of rapamycin chemical stability in volatile-organic solvents by HPLC

Drug-eluting coronary stents – focus on improved patient outcomes

Contact Info

Product

Resources

About

Use of rapamycin-impregnated stents in coronary arteries

Cited by 22 publications

References 17 publications

The Potential Role of mTOR Inhibitors in Non-Small Cell Lung Cancer

The Potential Role of mTOR Inhibitors in Non-Small Cell Lung Cancer

Evaluation of rapamycin chemical stability in volatile-organic solvents by HPLC

Drug-eluting coronary stents &ndash; focus on improved patient outcomes

Contact Info

Product

Resources

About

Drug-eluting coronary stents – focus on improved patient outcomes